about
sameAs
Evidence for a role of ADAM17 (TACE) in the regulation of platelet glycoprotein VThe disintegrin domain of ADAM9: a ligand for multiple beta1 renal integrinsIntegrin alpha5beta1 and ADAM-17 interact in vitro and co-localize in migrating HeLa cellsTumor necrosis factor-alpha converting enzyme in the human placenta throughout gestationDominant-negative effect of truncated mannose 6-phosphate/insulin-like growth factor II receptor species in cancerGroup 1 mGluR-dependent synaptic long-term depression: mechanisms and implications for circuitry and diseaseA Disintegrin and Metalloprotease (ADAM): Historical Overview of Their FunctionsScanning for Therapeutic Targets within the Cytokine Network of Idiopathic Inflammatory MyopathiesThe enzymatic activity of ADAM8 and ADAM9 is not regulated by TIMPsExtracellular phosphorylation of collagen XVII by ecto-casein kinase 2 inhibits ectodomain sheddingShedding of Collagen XVII/BP180: STRUCTURAL MOTIFS INFLUENCE CLEAVAGE FROM CELL SURFACEConservation and divergence of ADAM family proteins in the Xenopus genome.Sensitization of cerebral tissue in nude mice with photodynamic therapy induces ADAM17/TACE and promotes glioma cell invasion.Meltrin beta/ADAM19 interacting with EphA4 in developing neural cells participates in formation of the neuromuscular junction.Unexpected tolerance of alpha-cleavage of the prion protein to sequence variationsTumor Therapy Applying Membrane-bound Form of Cytokines.A macrophage cell model for selective metalloproteinase inhibitor designThe lack of ADAM17 activity during embryonic development causes hemorrhage and impairs vessel formation.The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversityA small region in the angiotensin-converting enzyme distal ectodomain is required for cleavage-secretion of the protein at the plasma membraneADAM17 activity and other mechanisms of soluble L-selectin production during death receptor-induced leukocyte apoptosis.Targeting the sheddase activity of ADAM17 by an anti-ADAM17 antibody D1(A12) inhibits head and neck squamous cell carcinoma cell proliferation and motility via blockage of bradykinin induced HERs transactivationAlpha1-antitrypsin monotherapy prolongs islet allograft survival in mice.miR-221/222 control luminal breast cancer tumor progression by regulating different targets.TIMP3: a physiological regulator of adult myogenesis.L1 is sequentially processed by two differently activated metalloproteases and presenilin/gamma-secretase and regulates neural cell adhesion, cell migration, and neurite outgrowthTransmembrane and trans-subunit regulation of ectodomain shedding of platelet glycoprotein Ibalpha.Modulation of CD163 expression by metalloprotease ADAM17 regulates porcine reproductive and respiratory syndrome virus entryRegulation of myogenic activation of p38 MAPK by TACE-mediated TNFα releaseCXCL16 signals via Gi, phosphatidylinositol 3-kinase, Akt, I kappa B kinase, and nuclear factor-kappa B and induces cell-cell adhesion and aortic smooth muscle cell proliferation.The Roles of ADAMs Family Proteinases in Skin DiseasesToxoplasma gondii inhibits toll-like receptor 4 ligand-induced mobilization of intracellular tumor necrosis factor alpha to the surface of mouse peritoneal neutrophils.TACE release of TNF-alpha mediates mechanotransduction-induced activation of p38 MAPK and myogenesis.The TNF-TNF receptor system.Novel therapies for the treatment of inflammatory airway disease.Metalloproteinases: their role in arthritis and potential as therapeutic targets.Ectodomain shedding of preadipocyte factor 1 (Pref-1) by tumor necrosis factor alpha converting enzyme (TACE) and inhibition of adipocyte differentiationPhysiologic and pathologic events mediated by intramembranous and juxtamembranous proteolysis.Lack of tissue inhibitor of metalloproteinases-3 results in an enhanced inflammatory response in antigen-induced arthritis.Extracellular proteases as targets for drug development
P2860
Q24293698-E2CF390F-01B0-4A11-B862-3613E789BE03Q24303582-1C581B18-B337-4ABD-AEB7-5E7993FE714FQ24309589-D469BB3E-8B1A-4F6A-B4B5-52E7BB7DD4C0Q24314291-D725A8F6-F5F7-4E7C-B68E-E353B06D38EDQ24337644-584A8FA0-711D-4E92-9ED2-A934B8D8106CQ24620534-B23E399E-055C-4881-B3D9-DDCAF1BD20C8Q26749364-0F8CB783-9EAA-45E5-AD30-965B436D788FQ26798209-7EC043E5-D5CD-44C3-806A-2DAFA67A147DQ28215674-5C4F4A24-C1DA-49C0-87D6-FEC5597C5F6CQ28304833-6B098BA6-A12F-4C1D-8C27-9C8323C1FDD6Q29013483-FD00DE03-E060-4655-9D72-3E740A13AC6CQ30432953-0D2F0467-7015-4098-946D-93B9F085B88FQ33325051-4934FFD4-854A-470D-9C53-F93023158C66Q33373332-3AE76D72-7FE2-4FAE-BC07-A71A6B4446E1Q33531737-3D3FCE64-2BAF-431F-ACFF-CAC83D926CDFQ33631960-43EF582C-B050-464A-B4AC-CE1BEC4BB169Q33680972-0CDA9280-C92F-47DE-9BC0-DCE47D11FFE4Q33728467-8DFB0881-824E-4C6E-A959-B87D74939FD3Q33786342-82307AB3-59DE-49B2-ACC7-FCF5D3CD0335Q33797731-CBE62718-4B00-413B-AD10-E083BA34BE83Q33805782-C8470738-E11E-453B-B09B-2C13D166EDC7Q33845082-BFBFCD8B-1E67-4CD0-96F6-3965BA5E5889Q33922982-F10F7F93-56FA-41F3-A249-7A94F52A48B0Q33952998-CD33DF26-E520-4434-A6D0-D194F42E6F91Q34072911-82766180-B4F9-4746-BB1C-35886961F584Q34097273-1092DB52-553B-4D81-B183-16D6B0F67AC5Q34186405-995EE8BD-27BF-4A17-8CCC-DBBCECCCBEB0Q34262328-8FB448A8-7229-427C-B34C-6AE4066104A8Q34391396-D62D73AE-5124-4AAF-B03B-8047D6A47CD6Q34649110-95550E4E-7C04-422B-AE6B-1330D0B4CFE7Q34669802-76ADE5F6-6183-4FB8-8578-DBD796A44D52Q34721141-5956D27C-0BA5-45C2-B63C-8AE17D41D460Q34997564-ADB0556A-4903-4B76-AA29-5B6D02E0C341Q35009296-060A5F1F-BC3A-4FE2-A5CC-9B9C570FA9DEQ35040779-AFB82A31-4EB6-4B34-AB18-7DA71D563231Q35056019-E931B91A-358E-4743-A87B-C30954BBFB6DQ35070932-FC8DFE63-CF43-466D-A638-758B9EF40866Q35079442-D69F68B5-6204-4D11-AA4C-1C2A62EB1C09Q35083869-B3EE329D-5AE4-4E55-8F25-94DE122EA27BQ35116202-0B373E28-757E-429C-BBED-20BE8C3E2037
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Tumor necrosis factor-alpha converting enzyme
@ast
Tumor necrosis factor-alpha converting enzyme
@en
Tumor necrosis factor-alpha converting enzyme
@nl
type
label
Tumor necrosis factor-alpha converting enzyme
@ast
Tumor necrosis factor-alpha converting enzyme
@en
Tumor necrosis factor-alpha converting enzyme
@nl
prefLabel
Tumor necrosis factor-alpha converting enzyme
@ast
Tumor necrosis factor-alpha converting enzyme
@en
Tumor necrosis factor-alpha converting enzyme
@nl
P3181
P1476
Tumor necrosis factor-alpha converting enzyme
@en
P2093
Roy A Black
P3181
P356
10.1016/S1357-2725(01)00097-8
P407
P577
2002-01-01T00:00:00Z